First, we noted that POLE/POLD1 exonuclease domain mutations were frequently clonal (13/15 POLE and 8/10 POLD1 mutations had an estimated cancer cell fraction [CCF] > 0.9) and that non-clonal POLE/POLD1 mutations appeared to be non-functional passenger events (Supplementary Figure 1). This evidence concerns the gene POLE and cancer.